Dr. Panken discusses study evaluating TRT and atrial fibrillation, acute kidney injury

In this video, Evan Panken, MD, discusses the study “Association of Testosterone Replacement Therapy With Atrial Fibrillation and Acute Kidney Injury,” which he presented at the 2024 Sexual Medicine Society of North America Annual Meeting in Scottsdale, Arizona. Panken is a urology resident at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Transcription:

How confident are you in the generalizability of these findings to the broader population of men with hypogonadism receiving TRT?

I think those are really important questions anytime you're doing database-based research. Obviously, data and publication findings are only as good as the data that goes in. I think with TriNetX, it's a pretty reliable network. It's a global federated database. Originally, they have over 109 million patients, 78 health care organizations. Last time I checked, that's probably increasing. I think some of the impetus for the creation of this database was to help find more patients who are eligible for clinical trials from the pharmaceutical side. But also, it presents a lot of data that can be looked into for the research side. I think with any database study, there are certain limitations, especially ours being retrospective, and there were some significant differences between the cohorts in terms of medical comorbidities, which is important to note. But I think that using this database does allow for some generalizability, and we're pretty confident in that.

This transcript was AI generated and edited by human editors for clarity.